With the recent integration of DaraRd at 1L, patients with MM are now more frequently exposed to and more likely to develop resistance to anti‐CD38 monoclonal antibodies during the initial stages of treatment [11]. The gene discussed is CD38; the disease is Miyoshi myopathy.